Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis

The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]

Celgene’s Fedratinib Given FDA Priority Review for New Drug Application in Myelofibrosis

PV Reporter was first to break the news on the Expanded Access Program for Fedratinib for Myelofibrosis Patients on November 16th, 2018. The next logical step for Celgene was filing for New Drug Application – Granted by the FDA on March 5th, 2019 Celgene Corporation announced today the U.S. Food and Drug Administration has accepted […]

Breaking news on Celgene’s Fedratinib for Myelofibrosis patients!

by David Wallace Fedratinib by Celgene, offered on Expanded Access Program (EAP) for Myelofibrosis Patients This is hot off the press!  So hot, that no one has covered it until now – brought to you by PV Reporter.  I knew after combing through the ASH (American Society of Hematology) abstracts that something was missing.  That […]

 
error: Content is protected !